The technology-driven pharmaceutical firm struck a deal with United Arab Emirates health authorities to bring artificial intelligence drug development tools to the region. Investor enthusiasm drove share prices higher as the company diversifies beyond traditional markets into the growing Middle Eastern biotech sector.